Use of Fatty Acids to Inhibit the Growth of Aneurysms

• US 20070231361A1
• Filed: 03/28/2006
• Published: 10/04/2007
• Est. Priority Date: 03/28/2006
• Status: Abandoned Application

• Current Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Original Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Inventors: Chu, Jack, Ganesan, Prema, Letort, Michel, Judd, Dianne, Brin, David, Tremble, Patrice, Tedeschi, Eugene
• Application Number:
  US11/277,637
• Publication Number:
  US 20070231361A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557

Abstract

Methods of treating an aneurysm in a patient in need thereof are provided. The methods comprise delivering to a treatment site an effective amount of a fatty acid inhibitor of a matrix metalloproteinase (MMP) such that the fatty acid inhibitor of the MMP causes the regression of a pre-existing aneurysm. Additionally, an implantable medical device is provided for implanting in a vessel wall of a patient comprising a structural support and a fatty acid inhibitor of an MMP.

Claims

1. A method of treating an aneurysm in a patient in need thereof comprising:

delivering to a treatment site an effective amount of a fatty acid inhibitor of a matrix metalloproteinase (MMP) such that said fatty acid inhibitor of said matrix metalloproteinase causes the regression of a pre-existing aneurysm.

2. The method according to claim 1 wherein said treatment site is an aneurysm site such as an aneurysm sac or a peri-sac region.

3. The method according to claim 1 wherein said fatty acid inhibitor of said MMP is elaidic acid or oleic acid.

4. The method according to claim 1 wherein said fatty acid inhibitor of said MMP is associated with a carrier substrate.

5. The method according to claim 4 wherein said carrier substrate is selected from the group consisting of biocompatible polymers, biocompatible biodegradable polymers, hydrogels and biological polymers.

6. The method according to claim 4 wherein said carrier substrate and said fatty acid inhibitor of said MMP take a form selected from the group consisting of a pellet, a gel, a stent and a mesh.

7. The method according to claim 6 wherein said pellet takes a form selected from the group consisting of particles, microparticles and microbeads.

8. The method according to claim 1 further comprising administering a stent graft to said treatment site.

9. The method according to claim 1 or 4 wherein said fatty acid inhibitor is delivered to said treatment site using an injection catheter.

10. An implantable medical device for implanting in a vessel wall of a patient comprising:

a structural support and a fatty acid inhibitor of a matrix metalloproteinase (MM P).

11. The implantable medical device according to claim 10 wherein said fatty acid inhibitor of said MMP is elaidic acid or oleic acid.

12. The implantable medical device according to claim 10 wherein said structural support is selected from the group consisting of a stent, a stent graft and a mesh.

13. The implantable medical device according to claim 10 wherein said fatty acid inhibitor of said MMP is coated on the vessel wall-contacting surface of said medical device.

14. The implantable medical device according to claim 13 wherein said fatty acid inhibitor of said MMP is coated on the vessel wall-contacting surface of said medical device in a biocompatible polymer coating